Q4 2023 13F Holders as of 31 Dec 2023
-
Type / Class
-
Equity / Common Stock, par value $0.0001 per share
-
Shares outstanding
-
98,567,360
-
Total 13F shares
-
65,423,068
-
Share change
-
-1,107,252
-
Total reported value
-
$358,517,051
-
Put/Call ratio
-
32%
-
Price per share
-
$5.48
-
Number of holders
-
99
-
Value change
-
-$2,784,476
-
Number of buys
-
47
-
Number of sells
-
43
Institutional Holders of ARS Pharmaceuticals, Inc. - Common Stock, par value $0.0001 per share (SPRY) as of Q4 2023
As of 31 Dec 2023 ARS Pharmaceuticals, Inc. - Common Stock, par value $0.0001 per share (SPRY) had 99 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions held a total of 65,423,068 shares of stock of the company.
Largest 10 holders included DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C), RA CAPITAL MANAGEMENT, L.P., ORBIMED ADVISORS LLC, FRANKLIN RESOURCES INC, SR ONE CAPITAL MANAGEMENT, LP, Charles Schwab Trust Co, K2 PRINCIPAL FUND, L.P., BlackRock Inc., VANGUARD GROUP INC, and BAKER BROS. ADVISORS LP.
This table shows 99 institutional shareholders of the security as of 31 Dec 2023.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.